查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
患者腫瘤組織移植 (PDX) 模型市場 - 全球市場規模、佔有率、趨勢分析、機會和預測報告（2019-2029）
市場調查報告書
商品編碼
1391776

患者腫瘤組織移植 (PDX) 模型市場 - 全球市場規模、佔有率、趨勢分析、機會和預測報告（2019-2029）

Patient-Derived Xenograft Model Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Tumor Type ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2029 年，患者腫瘤組織移植 (PDX) 模型的全球市場規模將成長一倍以上，達到 6.55 億美元

由於個人化醫療需求的不斷成長和癌症發病率的上升，全球患者腫瘤組織移植（PDX）模型市場正在蓬勃發展。

領先的策略諮詢和市場研究公司BlueWeave Consulting在最近的研究中估計，2022年全球患者腫瘤組織移植（PDX）模型市場規模為3.1256億美元。 BlueWeave 預測，在 2023 年至 2029 年的預測期內，患者腫瘤組織植入 (PDX) 模型的全球市場規模將以 13.1% 的年複合成長率顯著成長，到 2029 年將達到 6.5491 億美元。全球患者腫瘤組織移植（PDX）模型市場的主要成長動力包括癌症患者數量的增加、藥物研發活性化以及由於公共和私人對癌症研究的持續支持而對個體化藥物的需求。需求旺盛等在臨床前開發過程中，遵守美國FDA 的良好生產規範 (GMP) 至關重要。小型企業創新研究和小型企業技術轉移津貼等政府舉措為臨床前計畫提供財務支援和指導。全球對 PDX 模型的需求不斷增加，預計將簡化模型選擇和體內功效測試。 PDX 模型涉及將患者腫瘤組織直接移植到免疫力缺乏動物體內，保留重要的細胞-腫瘤相互作用，並已被證明可用於臨床前藥物測試和生物標記發現。免疫力缺乏大鼠的介紹有助於大鼠 PDX 模型的建立。擴大研發活動以及政府和私營部門對癌症研究的持續支持正在推動市場成長。然而，在分析期間，高成本、技術專長、道德問題預計將抑制整體市場的成長。

該報告的詳細分析提供了有關全球患者腫瘤組織植入（PDX）模型市場的成長潛力、未來趨勢和統計數據的資訊。我們也研究了推動市場總規模預測的因素。該報告致力於提供全球患者腫瘤組織植入（PDX）模型市場的最新技術趨勢以及產業見解，以幫助決策者做出策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球患者腫瘤組織植入（PDX）模型市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 個人化醫療需求不斷成長
      • 癌症發生率增加
    • 抑制因素
      • 高成本和技術專長
      • 道德問題
    • 機會
      • 擴大研發
      • 協作與夥伴關係
    • 任務
      • 模型變異性
      • 監管障礙
  • 科技進步/最新發展
  • 法律規範
  • 波特五力分析

第4章 全球病患腫瘤組織移植（PDX）模型市場概述

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
      • 小鼠模型
      • 大鼠模型
    • 按腫瘤類型
      • 胃腸道腫瘤模型
      • 婦科腫瘤模型
      • 呼吸道腫瘤模型
      • 泌尿系統腫瘤模型
      • 血液腫瘤模型
      • 其他
    • 按最終用戶
      • 製藥和生物技術公司
      • 學術研究所
      • 其他
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區
      • 中美洲和南美洲
      • 中東/非洲

第5章 北美病患腫瘤組織移植（PDX）模型市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按腫瘤類型
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲病患腫瘤組織移植（PDX）模型市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按腫瘤類型
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第7章 亞太病患腫瘤組織移植（PDX）模型市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按腫瘤類型
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 其他亞太地區

第8章 拉丁美洲患者腫瘤組織移植（PDX）模型市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按腫瘤類型
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他中美洲和南美洲

第9章 中東和非洲病患腫瘤組織移植（PDX）模型市場

  • 市場規模及預測（2019-2029）
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按腫瘤類型
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第10章 競爭形勢

  • 主要企業及其產品列表
  • 全球患者腫瘤組織移植 (PDX) 模型市場佔有率分析 (2022)
  • 透過管理參數進行競爭基準化分析
  • 主要策略發展（合併、收購、合作夥伴關係等）

第11章COVID-19 對全球病患腫瘤組織移植（PDX）模型市場的影響

第12章公司簡介（公司簡介、財務矩陣、競爭形勢、關鍵人力資源、主要競爭、聯絡地址、策略展望、SWOT分析）

  • JSR Corporation
  • Wuxi Apptec
  • The Jackson Laboratory
  • Charles River Laboratories International, Inc.
  • Taconic Biosciences, Inc.
  • Oncodesign Precision Medicine
  • Inotiv, Inc.
  • Pharmatest Services
  • Hera BioLabs
  • EPO Berlin-Buch GmbH
  • Xentech
  • Urosphere
  • Altogen Labs
  • Abnova Corporation
  • 其他主要企業

第13章主要戰略建議

第14章調查方法

簡介目錄
Product Code: BWC23932

Global Patient-Derived Xenograft (PDX) Model Market Size More Than Doubles to Touch USD 655 Million by 2029.

Global patient-derived xenograft (PDX) model market is flourishing because of the rising demand for personalized medicine and growing cancer incidence.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global patient-derived xenograft (PDX) model market size at USD 312.56 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global patient-derived xenograft (PDX) model market size to grow at a significant CAGR of 13.1% reaching a value of USD 654.91 million by 2029. Major growth drivers for the global patient-derived xenograft model market include an increasing cancer case, heightened pharmaceutical R&D, and rising demand for personalized medicines with continued support from public and private sectors for cancer research. Adherence to the US FDA Good Manufacturing Practices (GMPs) is crucial in preclinical development. Governments' initiatives, like Small Business Innovative Research and Small Business Technology Transfer Grants, offer financial support and guidance for preclinical programs. Anticipated PDX model demand is rising globally, simplifying model selection and in vivo efficacy trials. The PDX model involves direct implantation of patient tumor tissue into immune-compromised animals, preserving vital cell-tumor interactions and proving valuable in preclinical drug testing and biomarker discovery. The introduction of immunodeficient rats will facilitate PDX models in rats. Expanding R&D activities and consistent government and private sector support for cancer research drive market growth. However, high cost and technical expertise and ethical concerns are anticipated to restrain the overall market growth during the period in analysis.

Global Patient-Derived Xenograft (PDX) Model Market - Overview

The global patient-derived xenograft (PDX) model market refers to the market encompassing the use of specialized laboratory mice or other animals to implant human tumor tissues. These PDX models are created by directly transplanting cancerous tissue from a patient into an immune-deficient animal, preserving the essential interactions between human cancer cells and the surrounding microenvironment. They serve as vital tools for preclinical research in oncology, allowing scientists and researchers to study the behavior of human tumors in a more clinically relevant setting. The market includes the development, utilization, and supply of PDX models to facilitate drug testing, biomarker discovery, and co-clinical investigations in the quest for more effective cancer treatments and personalized medicine.

Impact of COVID-19 on Global Patient-derived xenograft (PDX) model Market

COVID-19 pandemic adversely affected the global patient-derived xenograft (PDX) model market. With lockdowns, restrictions on laboratory operations, and supply chain interruptions, research activities were temporarily halted or delayed. Access to resources and animal models required for PDX model development became constrained. Furthermore, prioritization of COVID-19 research led to a diversion of resources and funding. However, as the pandemic highlighted the importance of personalized medicine, it also emphasized the significance of PDX models in cancer research. As restrictions eased, the market rebounded, driven by the growing need for innovative cancer treatments and therapies.

Global Patient-Derived Xenograft (PDX) Model Market - By Tumor Type

Based on tumor type, the global patient-derived xenograft (PDX) model market is divided into Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, Urological Tumor Models, and Hematological Tumor Models segments. The respiratory tumor model segment holds the highest share in the global patient derived xenograft model market by tumor type, due to the increased prevalence of respiratory cancers worldwide, leading to a heightened focus on developing models to study these tumors. Lung cancer, for instance, remains a leading cause of cancer-related deaths globally, necessitating a robust platform for research. PDX models for respiratory tumors enable researchers to closely mimic and study these cancers in vivo, facilitating the development of innovative therapies and treatment strategies. This growing demand for effective respiratory tumor models propels the segment's dominance in the global PDX model market.

Competitive Landscape

Major players operating in the global patient-derived xenograft (PDX) model market include: JSR Corporation, Wuxi Apptec, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., Pharmatest Services, Hera BioLabs, EPO Berlin-Buch GmbH, Xentech, Urosphere, Altogen Labs, and Abnova Corporation. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Patient-Derived Xenograft (PDX) Model Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Patient-Derived Xenograft (PDX) Model Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Patient-Derived Xenograft (PDX) Model Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising demand for personalized medicine
      • 3.2.1.2. Growing cancer incidence
    • 3.2.2. Restraints
      • 3.2.2.1. High cost and technical expertise
      • 3.2.2.2. Ethical concerns
    • 3.2.3. Opportunities
      • 3.2.3.1. Expansion in research and development
      • 3.2.3.2. Collaborations and partnerships
    • 3.2.4. Challenges
      • 3.2.4.1. Model variability
      • 3.2.4.2. Regulatory hurdles
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Patient-Derived Xenograft (PDX) Model Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Mice Model
      • 4.2.1.2. Rats Model
    • 4.2.2. By Tumor Type
      • 4.2.2.1. Gastrointestinal Tumor Model
      • 4.2.2.2. Gynecological Tumor Model
      • 4.2.2.3. Respiratory Tumor Model
      • 4.2.2.4. Urological Tumor Models
      • 4.2.2.5. Hematological Tumor Models
      • 4.2.2.6. Others
    • 4.2.3. By End User
      • 4.2.3.1. Pharmaceutical & Biotechnology Companies
      • 4.2.3.2. Academic & Research Institutions
      • 4.2.3.3. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Patient-Derived Xenograft (PDX) Model Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Tumor Type
    • 5.2.3. By End User
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Type
      • 5.2.4.1.2. By Tumor Type
      • 5.2.4.1.3. By End User
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Type
      • 5.2.4.2.2. By Tumor Type
      • 5.2.4.2.3. By End User

6. Europe Patient-Derived Xenograft (PDX) Model Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Tumor Type
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Type
      • 6.2.4.1.2. By Tumor Type
      • 6.2.4.1.3. By End User
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Type
      • 6.2.4.2.2. By Tumor Type
      • 6.2.4.2.3. By End User
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Type
      • 6.2.4.3.2. By Tumor Type
      • 6.2.4.3.3. By End User
      • 6.2.4.4. France
      • 6.2.4.4.1. By Type
      • 6.2.4.4.2. By Tumor Type
      • 6.2.4.4.3. By End User
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Type
      • 6.2.4.5.2. By Tumor Type
      • 6.2.4.5.3. By End User
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Type
      • 6.2.4.6.2. By Tumor Type
      • 6.2.4.6.3. By End User
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Type
      • 6.2.4.7.2. By Tumor Type
      • 6.2.4.7.3. By End User
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Type
      • 6.2.4.8.2. By Tumor Type
      • 6.2.4.8.3. By End User
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Type
      • 6.2.4.9.2. By Tumor Type
      • 6.2.4.9.3. By End User

7. Asia-Pacific Patient-Derived Xenograft (PDX) Model Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Tumor Type
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Type
      • 7.2.4.1.2. By Tumor Type
      • 7.2.4.1.3. By End User
      • 7.2.4.2. India
      • 7.2.4.2.1. By Type
      • 7.2.4.2.2. By Tumor Type
      • 7.2.4.2.3. By End User
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Type
      • 7.2.4.3.2. By Tumor Type
      • 7.2.4.3.3. By End User
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Type
      • 7.2.4.4.2. By Tumor Type
      • 7.2.4.4.3. By End User
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Type
      • 7.2.4.5.2. By Tumor Type
      • 7.2.4.5.3. By End User
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Type
      • 7.2.4.6.2. By Tumor Type
      • 7.2.4.6.3. By End User
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Type
      • 7.2.4.7.2. By Tumor Type
      • 7.2.4.7.3. By End User
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Type
      • 7.2.4.8.2. By Tumor Type
      • 7.2.4.8.3. By End User
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Type
      • 7.2.4.9.2. By Tumor Type
      • 7.2.4.9.3. By End User
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Type
      • 7.2.4.10.2. By Tumor Type
      • 7.2.4.10.3. By End User

8. Latin America Patient-Derived Xenograft (PDX) Model Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Tumor Type
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Tumor Type
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Tumor Type
      • 8.2.4.2.3. By End User
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Type
      • 8.2.4.3.2. By Tumor Type
      • 8.2.4.3.3. By End User
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Type
      • 8.2.4.4.2. By Tumor Type
      • 8.2.4.4.3. By End User
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Type
      • 8.2.4.5.2. By Tumor Type
      • 8.2.4.5.3. By End User

9. Middle East & Africa Patient-Derived Xenograft (PDX) Model Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Tumor Type
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Tumor Type
      • 9.2.4.1.3. By End User
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Tumor Type
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Tumor Type
      • 9.2.4.3.3. By End User
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Tumor Type
      • 9.2.4.4.3. By End User
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Tumor Type
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Tumor Type
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Tumor Type
      • 9.2.4.7.3. By End User
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Tumor Type
      • 9.2.4.8.3. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Patient-Derived Xenograft (PDX) Model Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Patient-Derived Xenograft (PDX) Model Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. JSR Corporation
  • 12.2. Wuxi Apptec
  • 12.3. The Jackson Laboratory
  • 12.4. Charles River Laboratories International, Inc.
  • 12.5. Taconic Biosciences, Inc.
  • 12.6. Oncodesign Precision Medicine
  • 12.7. Inotiv, Inc.
  • 12.8. Pharmatest Services
  • 12.9. Hera BioLabs
  • 12.10. EPO Berlin-Buch GmbH
  • 12.11. Xentech
  • 12.12. Urosphere
  • 12.13. Altogen Labs
  • 12.14. Abnova Corporation
  • 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations